MicroRNA-137/181c Regulates Serine Palmitoyltransferase and In Turn Amyloid , Novel Targets in Sporadic Alzheimer's Disease

Genetics Program, Michigan State University, East Lansing, Michigan 48824, USA.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 10/2011; 31(41):14820-30. DOI: 10.1523/JNEUROSCI.3883-11.2011
Source: PubMed


The contribution of mutations in amyloid precursor protein (APP) and presenilin (PSEN) to familial Alzheimer's disease (AD) is well established. However, little is known about the molecular mechanisms leading to amyloid β (Aβ) generation in sporadic AD. Increased brain ceramide levels have been associated with sporadic AD, and are a suggested risk factor. Serine palmitoyltransferase (SPT) is the first rate-limiting enzyme in the de novo ceramide synthesis. However, the regulation of SPT is not yet understood. Evidence suggests that it may be posttranscriptionally regulated. Therefore, we investigated the role of miRNAs in the regulation of SPT and amyloid β (Aβ) generation. We show that SPT is upregulated in a subgroup of sporadic AD patient brains. This is further confirmed in mouse model studies of risk factors associated with AD. We identified that the loss of miR-137, -181c, -9, and 29a/b-1 increases SPT and in turn Aβ levels, and provides a mechanism for the elevated risk of AD associated with age, high-saturated-fat diet, and gender. Finally, these results suggest SPT and the respective miRNAs may be potential therapeutic targets for sporadic AD.

Download full-text


Available from: Christina Chan
  • Source
    • "miR-137 is likely a central factor coordinating the timing and expression of multiple schizophrenia risk genes, especially those related to neuronal differentiation and proliferation [2, 8, 10, 24, 31, 32]. Thus, we suspect that dysregulation of miR-137 expression and the subsequent abnormal expression of miR-137 target genes contribute to the neurodevelopment, disease progression, and neuromorphological pathologies present in schizophrenia [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Both genome wide association study (GWAS) and biochemical studies of Caucasian populations indicate a robust association between the miR-137 genetic variant rs1625579 and schizophrenia, but inconsistent results have been reported. To assay the association between this variant and schizophrenia, we genotyped 611 schizophrenic patients from Southern Chinese Han population for the risk single nucleotide polymorphism (SNP) rs1625579 using the SNaPshot technique and compared the clinical profiles of different genotypes. Additionally, a meta-analysis was performed using the combined sample groups from five case-control publications and the present study. Both the genotype and allele distributions of the rs1625579 SNP were significantly different between patients and controls (P = 0.036 and 0.026, SNP). TT genotype carriers showed slightly lower Brief Assessment of Cognition in Schizophrenia- (BACS-) derived working memory performance than G carriers (15.58 ± 9.56 versus 19.71 ± 8.18, P = 0.045). In the meta-analysis, we observed a significant association between rs1625579 and schizophrenia under different genetic models (all P < 0.05). The results of our study and meta-analysis provide convincing evidence that rs1625579 is significantly associated with schizophrenia. Furthermore, the miR-137 polymorphism influences the working memory performance of schizophrenic patients in a Chinese Han population.
    Full-text · Article · Aug 2014 · BioMed Research International
  • Source
    • "The mRNA levels of hnRNPA1 were observed to be negatively correlated with miR-590-3p levels, supporting the hypothesis that this miRNA acts as a regulator of hnRNPA1, therefore influencing APP production (Villa et al., 2011). Another study on candidate miRNAs, previously found to be reduced in post-mortem brain cortices of AD patients (Geekiyanage and Chan, 2011), described a downregulation of 4 of these (among them, miR 29a/b) in the serum of individuals suffering from mild cognitive impairment (MCI) or AD (Geekiyanage et al., 2012). This consistency of results indicates that peripheral blood and its derivatives represent valid tissues to study miRNAs in CNS diseases, as they could reflect brain alterations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: microRNAs (miRNAs) are small non-coding RNAs (20-22 nucleotides) playing a major role in post-transcriptional regulation of gene expression. miRNAs are predicted to regulate more than 50% of all the protein-coding genes. Increasing evidence indicates that they may play key roles in the biological pathways that regulate neurogenesis and synaptic plasticity, as well as in neurotransmitter homeostasis in the adult brain. In this article we review recent studies suggesting that miRNAs may be involved in the pathophysiology of neuropsychiatric disorders and in the action of psychotropic drugs, in particular by analyzing the contribution of genomic studies in patients' peripheral tissues. Alterations in miRNA expression have been observed in schizophrenia, bipolar disorder, major depression, Parkinson's disease, Alzheimer's disease and other neuropsychiatric conditions. In particular, intriguing findings concern the identification of disease-associated miRNA signatures in peripheral tissues, or modifications in miRNA profiles induced by drug treatments. Furthermore, genetic variations in miRNA sequences and miRNA-related genes have been described in neuropsychiatric diseases. Overall, though still at a preliminary stage, several lines of evidence indicate an involvement of miRNAs in both the pathophysiology and pharmacotherapy of neuropsychiatric disorders. In this regard, the data obtained in peripheral tissues may provide further insights into the etiopathogenesis of several brain diseases and contribute to identify new biomarkers for diagnostic assessment improvement and treatment personalization.
    Full-text · Article · Mar 2014 · Frontiers in Cellular Neuroscience
  • Source
    • "Geekiyanage et al. (2012) compared concentrations of five miRNA, namely miR-137, miR-181c, miR-9, miR-29a, and miR-29b in serum of MCI and AD patients with their levels in serum of age-matched controls. The choice of miRNA was based on the previous study (Geekiyanage and Chan, 2011) that demonstrated their involvement in AD pathogenesis and downregulation of these miRNA in the brain cortex of sporadic AD patients. Using RT-PCR and normalization per spiked cel-miR-39 and internal miR-22, miR-191, and miR-126 the authors demonstrated that the levels of miR-137, miR-181c, miR-9, miR-29a, and miR-29b are significantly lower in serum of MCI and AD patients, compared to controls. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many neurodegenerative diseases, such as Alzheimer's disease, Parkinson disease, vascular and frontotemporal dementias, as well as other chronic neurological pathologies, are characterized by slow development with a long asymptomatic period followed by a stage with mild clinical symptoms. As a consequence, these serious pathologies are diagnosed late in the course of a disease, when massive death of neurons has already occurred and effective therapeutic intervention is problematic. Thus, the development of screening tests capable of detecting neurodegenerative diseases during early, preferably asymptomatic, stages is a high unmet need. Since such tests are to be used for screening of large populations, they should be non-invasive and relatively inexpensive. Further, while subjects identified by screening tests can be further tested with more invasive and expensive methods, e.g., analysis of cerebrospinal fluid or imaging techniques, to be of practical utility screening tests should have high sensitivity and specificity. In this review, we discuss advantages and disadvantages of various approaches to developing screening tests based on analysis of circulating cell-free microRNA (miRNA). Applications of circulating miRNA-based tests for diagnosis of acute and chronic brain pathologies, for research of normal brain aging, and for disease and treatment monitoring are also discussed.
    Full-text · Article · Sep 2013 · Frontiers in Cellular Neuroscience
Show more